KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Goodwill (2016 - 2022)

Nektar Therapeutics (NKTR) has 13 years of Goodwill data on record, last reported at $76.5 million in Q4 2022.

  • For Q4 2022, Goodwill changed 0.0% year-over-year to $76.5 million; the TTM value through Dec 2022 reached $76.5 million, changed 0.0%, while the annual FY2022 figure was $76.5 million, 0.0% changed from the prior year.
  • Goodwill reached $76.5 million in Q4 2022 per NKTR's latest filing, roughly flat from $76.5 million in the prior quarter.
  • Across five years, Goodwill topped out at $76.5 million in Q1 2018 and bottomed at $76.5 million in Q1 2018.
  • Average Goodwill over 5 years is $76.5 million, with a median of $76.5 million recorded in 2018.
  • The widest YoY moves for Goodwill: up 0.0% in 2018, down 0.0% in 2018.
  • A 5-year view of Goodwill shows it stood at $76.5 million in 2018, then changed by 0.0% to $76.5 million in 2019, then changed by 0.0% to $76.5 million in 2020, then changed by 0.0% to $76.5 million in 2021, then changed by 0.0% to $76.5 million in 2022.
  • Per Business Quant database, its latest 3 readings for Goodwill were $76.5 million in Q4 2022, $76.5 million in Q3 2022, and $76.5 million in Q2 2022.